Free Trial
LON:SAR

Sareum (SAR) Share Price, News & Analysis

Sareum logo
GBX 16.68 -0.32 (-1.88%)
As of 05/2/2025 11:16 AM Eastern

About Sareum Stock (LON:SAR)

Key Stats

Today's Range
16.68
17.55
50-Day Range
11.45
20.50
52-Week Range
11
52.50
Volume
180,656 shs
Average Volume
495,775 shs
Market Capitalization
£20.84 million
P/E Ratio
N/A
Dividend Yield
1.10%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802). Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance. Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com

Receive SAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter.

SAR Stock News Headlines

Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
Sareum Holdings Refocuses Strategy After SRA737 Licensing Termination
See More Headlines

SAR Stock Analysis - Frequently Asked Questions

Sareum's stock was trading at GBX 24.60 at the beginning of the year. Since then, SAR stock has decreased by 32.2% and is now trading at GBX 16.68.
View the best growth stocks for 2025 here
.

Sareum Holdings plc (LON:SAR) announced its quarterly earnings results on Tuesday, March, 25th. The company reported ($0.90) earnings per share (EPS) for the quarter.

Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP) and Summit Therapeutics (SMMT).

Company Calendar

Last Earnings
3/25/2025
Today
5/02/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
Financial Services
Current Symbol
LON:SAR
CIK
N/A
Fax
N/A
Employees
3,211
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-5,275,221.97
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 1.47 per share
Price / Cash Flow
11.32
Book Value
GBX 2.61 per share
Price / Book
6.39

Miscellaneous

Free Float
N/A
Market Cap
£20.84 million
Optionable
Not Optionable
Beta
-1.08
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (LON:SAR) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners